Open-label trial of acamprosate as a treatment for anxiety

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 11, Issue 5, 2009, Pages 267-

  Hertzman, Marc ^a   Patt, Ivy S ^a   Spielman, Lisa A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649931262     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.08l00714     Document Type: Letter

References (6)

1. Kiefer F, Helwig H, Tarnaske T, et al. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res. 2005;11(2):83-91.
2. Verheul R, Lehert P, Geerlings PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl). 2005;178(2-3):167-173.
3. Cammack J, Ghasemzadee B, Adams R. The pharmacological profile of glutamate-evoked ascorbic acid efflux measured by in vivo electrochemistry. Brain Res. 1991;565(1):17-22.
4. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222.
5. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
6. Zung WWK. A rating instrument for anxiety disorders. Psychosomatics. 1971;12:371-379.